title: Treatment of subretinal fluid associated with dome-shaped macula.
abstract: Dome-shaped macula is a recently described disorder seen in eyes with myopic posterior staphyloma. Vision loss may accompany sub-macular fluid accumulation, for which no effective treatment has been reported. The authors report the successful treatment of two female patients, aged 34 and 59 years, with chronic exudative macular detachment associated with dome-shaped macula. Symptoms of subretinal fluid had been present for at least 2 years in each case, and the fluid was refractory to multiple intravitreal bevacizumab injections in one eye. After a single session of half-fluence verteporfin photodynamic therapy, the submacular fluid resolved completely in each eye. In one eye, recurrent submacular fluid 2 years later responded partially to repeat photodynamic therapy and completely to focal laser photocoagulation. [Ophthalmic Surg Lasers Imaging Retina. 2013;44:593-595.].
authors.forename: Nicholas D
authors.initials: ND
authors.lastname: Chinskey
authors.forename: Mark W
authors.initials: MW
authors.lastname: Johnson
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002908:Chronic Disease; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D017075:Laser Coagulation / Q000379:methods; D008266:Macula Lutea / Q000002:abnormalities*; D008875:Middle Aged; D010778:Photochemotherapy; D012163:Retinal Detachment / Q000628:therapy; D012164:Retinal Diseases / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab